Investing.com -- Moderna (NASDAQ: NASDAQ: MRNA) stock declined 4.9% and BioNTech SE (NASDAQ: NASDAQ: BNTX) shares fell 1.5% ...

BofA lowered the firm’s price target on BioNTech (BNTX) to $147 from $150 and keeps a Buy rating on the shares. On the Q4 call, the firm will ...

BioNTech SE (NASDAQ:BNTX), a biotechnology company renowned for its mRNA technology platform and COVID-19 vaccine success, is navigating a crucial phase in its evolution. With a market capitalization ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...

We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.

The Goldman Sachs Group raised BioNTech from a “neutral” rating to a “buy” rating and raised their price target for the stock from $90.00 to $137.00 in a research report on Friday ...

BioNTech SE (NASDAQ:BNTX), a biotechnology ... with a decrease expected in 2024 compared to 2023. The company's stock price has experienced volatility, partly due to market conditions and ...

The firm issued a buy rating and a $172.00 price objective on the stock. A number of other analysts have also weighed in on the stock. Jefferies Financial Group upgraded shares of BioNTech from a ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T ...

Truist sets BioNTech's price target at $172 ... contributing over $4 billion in revenue. Price Action: BNTX stock is up 0.55% at $122.82 at last check Friday.